Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

458
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
458
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

675
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
675

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Contextual assessment of health system alignment with National Standards for Cancer Survivorship Care in the American Southeast.

Research square·2026
Same author

Microsurgical outcomes of free flaps in patients with sickle cell trait: A case series.

JPRAS open·2026
Same author

Supportive oncology and the USA Cancer Moonshot: academic, clinical and operational opportunities.

BMJ supportive & palliative care·2026
Same author

Baseline Body Composition Characteristics and Overall Survival in Young Women with Breast Cancer: Matched Case-Control Study Nested Within a Cohort.

Tomography (Ann Arbor, Mich.)·2026
Same author

Cancer patient navigation: program development in a large multisite cancer institute (2010-2023).

BMJ supportive & palliative care·2026
Same author

Prevalence and Correlates of Sleep Difficulties in a Large Multicenter Outpatient Oncology Population as Identified through Practice-Based Screening.

Cancer research communications·2026

相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

支持性瘤学景观:当前状态

Ye M Aung1,2, Jake Waldman3, Jacquelyn Jackson3,4

  • 1Department of Supportive Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. lawrence.aung@atriumhealth.org.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
|June 23, 2025
PubMed
概括

支持性瘤服务在癌症护理实体内不一致地提供和组织. 需要正式的标准来改善患者支持和全面的癌症护理服务.

关键词:
癌症 癌症 癌症 癌症综合癌症中心综合癌症中心服务交付服务的交付.支持性护理是一种支持性护理.支持性瘤学 支持性瘤学

更多相关视频

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

7.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

相关实验视频

Last Updated: Sep 18, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

7.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

科学领域:

  • 在瘤学瘤学.
  • 医疗保健管理的管理
  • 患者支持服务服务.

背景情况:

  • 癌症治疗已经进步,增加了生存率,但也增加了与治疗相关的副作用.
  • 支持性瘤学服务旨在管理癌症和与治疗相关的发病率.
  • 目前的支持性瘤服务缺乏一致的可用性和组织.

研究的目的:

  • 评估支持性瘤服务的可用性和组织.
  • 为了确定跨癌症护理实体的服务提供中存在的差异.
  • 为了强调对标准化的支持性护理的需要.

主要方法:

  • 进行了谷歌搜索,寻找支持性瘤学项目和服务.
  • 根据预先定义的标准,分析了88个癌症护理实体 (CCE).
  • 对服务组织和领导的描述性语言进行了审查.

主要成果:

  • 支持小组是最常见的服务 (86%);老年瘤是最不常见的 (21%).
  • 国家癌症研究所指定的综合癌症中心 (NCI-CCC) 提供了更多服务.
  • 只有9%的实体有正式的支持性瘤科;51%的人称之为"服务".

结论:

  • 在支持性瘤学服务提供中存在显著的异质性.
  • 这些重要服务的非正式组织是一个主要问题.
  • 来自NCI和其他机构的正式标准对于改善癌症护理支持至关重要.